Pertussis vaccine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Pertussis vaccine
Accession Number
DB15274
Description

Pertussis vaccine is under investigation in clinical trial NCT01698346 (Pertussis (Tdap) Vaccination in Pregnancy).

Type
Biotech
Groups
Approved, Investigational
Synonyms
  • Bordetella pertussis

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Abatacept.
AdalimumabThe therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Adalimumab.
AldesleukinThe therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Aldesleukin.
AlefaceptThe therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Alefacept.
AlemtuzumabThe therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Alemtuzumab.
AltretamineThe therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Altretamine.
AmsacrineThe therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Amsacrine.
AnakinraThe therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Anakinra.
Antilymphocyte immunoglobulin (horse)The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Antilymphocyte immunoglobulin (horse).
Antithymocyte immunoglobulin (rabbit)The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Purchasing individual compounds or compound libraries for your research?
Learn More
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Pertussis Vaccine 4 Protect UnitSuspensionSubcutaneousAventis Pasteur Limited1921-12-312001-07-19Canada flag
Additional Data Available
  • Application Number
    Application Number
    Available for Purchase

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code
    Available for Purchase

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Diphtheria and Tetanus Toxoids With Pertussis Vaccine AdsorbedPertussis vaccine (12 unit) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 lf) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (25 lf)LiquidIntramuscularAventis Pasteur Limited1980-12-312001-07-19Canada flag
Tri-immunol Liq ImPertussis vaccine (4 unit) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 lf) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (12.5 lf)LiquidIntramuscularLederle Labs, Division of American Cyanamid Co1993-12-312001-06-05Canada flag

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
2QNL82089R
CAS number
Not Available

References

General References
Not Available
RxNav
1608803
Wikipedia
Pertussis_vaccine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionDiphtheria / Pertussis / Tetanus1
4CompletedPreventionDiphtheria / Pertussis / Tetanus / Whooping Cough2
4CompletedPreventionFebrile Convulsions / Fever / Fever After Vaccination1
4CompletedPreventionHealthy Volunteers1
4CompletedPreventionInfluenza, Human1
4CompletedPreventionMeningococcal Meningitis1
4CompletedPreventionPertussis / Pregnancy1
4CompletedPreventionPregnancy1
4Not Yet RecruitingPreventionDiphtheria Immunisation / Pertussis Immunisation / Polyomyelitis Vaccine / Tetanus Immunisation1
4RecruitingPreventionApnea / Apnoea neonatal / Infants, Premature1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, suspensionIntramuscular8 μg
Injection, solutionIntramuscular8 mcg/0.5ml
Injection, suspension30 iu/0.5mL
LiquidIntramuscular
Injection, suspensionParenteral20 mcg
Injection, powder, for suspensionIntramuscular25 mcg
Injection, powder, for suspensionIntramuscular10 mcg
Injection, powder, for suspensionIntramuscular25 mcg/0.5ml
InjectionIntramuscular30 IU
SuspensionSubcutaneous
Injection, suspensionIntramuscular40 IU/0.5mL
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on May 20, 2019 09:06 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates